Nuformix plc (LON:NFX – Get Free Report) hit a new 52-week low during mid-day trading on Wednesday. The company traded as low as GBX 0.09 and last traded at GBX 0.10, with a volume of 4,712,799 shares changing hands. The stock had previously closed at GBX 0.10.
Nuformix Price Performance
The business has a 50 day simple moving average of GBX 0.13 and a 200 day simple moving average of GBX 0.18. The company has a market capitalization of £2.66 million, a price-to-earnings ratio of -3.48 and a beta of 1.53.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Featured Stories
- Five stocks we like better than Nuformix
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
